Phase I
Moderna published second interim analysis of its open-label Phase I trial of its COVID-19 vaccine, mRNA-1273, in The New England Journal of Medicine.
Although still preliminary, Regeneron Pharmaceuticals announced early data from its Phase I/II/III trial of its antibody cocktail, REGN-COV2, against COVID-19.
The importance of diversity of patients in clinical studies cannot be overlooked, nor can the importance of diversity at the C-suite level. But, it’s equally important to have a diverse clinical research team as well.
The company posted an interim analysis of its Phase I/IIa trial that showed a single dose of JNJ-78436735 induced a strong neutralizing antibody response in nearly all participants and was well-tolerated.
The European Society of Medical Oncology (ESMO) Virtual Congress 2020 was last weekend and the beginning of the week, which resulted in numerous clinical trial announcements. Here’s a look.
Arcturus CEO Joseph Payne told BioSpace in an interview that his company’s vaccine candidate is a low-dose, single-shot treatment that generated not only neutralizing antibody titers, but also CD8+ T-cell induction in preclinical studies.
Please check out the biopharma industry coronavirus (COVID-19) stories that are trending for October 2, 2020.
Please check out the biopharma industry coronavirus (COVID-19) stories that are trending for September 30, 2020.
Please check out the biopharma industry coronavirus (COVID-19) stories that are trending for September 28, 2020.
Please check out the biopharma industry coronavirus (COVID-19) stories that are trending for September 25, 2020.
PRESS RELEASES